Biovest to Present at Active Immunotherapeutics Forum
TAMPA, Fla. & MINNEAPOLIS, Minn.--(BUSINESS WIRE)--Jun 15, 2010 - Biovest International, Inc. (Pink Sheets: BVTI) today announced that the Company will present the ongoing commercial development of the Company's personalized cancer vaccine, BiovaxID®, on June 22nd at the Active Immunotherapeutics Forum 2010 in Barcelona, Spain.
According the Conference's marketing materials, highlights of the meeting include case studies on Provenge®, StimuvaxR®, Oncophage® and BiovaxID® – all delivered by senior pioneers in their field: Dr. Mitchell Gold, Dendreon; Dr. Jens-Peter Marschner, Merck KGaA; Dr. Daniel L. Levey, Antigenics; and Dr. Carlos F. Santos, Biovest International.
Biovest's Vice President, Product Development & Regulatory Affairs, Dr. Carlos F. Santos, will deliver a presentation titled, “Clinical development of BiovaxID (fNHL-Id) vaccine for Non-Hodgkin's Lymphoma”, discussing the Company's positive Phase II and Phase III clinical trial results and regulatory plans.
According to Dr. Santos, “The agenda for this conference recognizes Biovest as a pioneer in the field of cancer vaccines, and we look forward to sharing our results and plans with industry peers and leading research institutions. We will discuss the ongoing development and opportunities arising from the success of our late-stage development program for BiovaxID. The successful outcomes in our Phase III clinical trial for treatment of non-Hodgkin's lymphoma follow a number of Phase II studies demonstrating that our vaccine can prolong remission as well as induce potent and durable anti-tumor immune responses in treated patients. We also intend to present our future development plans for BiovaxID, including a discussion of the results of an open-label clinical trial for an aggressive type of lymphoma for which there is no currently-defined consensus standard-of-care. Importantly, I believe the results of this study illustrate that the safety and immune responses induced by BiovaxID are maintained in the context of rituximab-containing chemotherapy regimens.”
Event: Active Immunotherapeutics Forum 2010
Place: The Fira Palace, Barcelona, Spain
Biovest Presentation Day/Time: Tuesday, June 22nd at 10:00 a.m.
On Wednesday, June 23rd at 9:30 a.m., Dr. Santos will also participate in an expert panel session titled, “What are the recent advances in B-cell and antibody approaches to active immunotherapeutics, and how are they being used to inform decisions in different disease areas?”
If conference attendees are interested in scheduling a one-on-one meeting with Dr. Santos at this event, please contact Douglas Calder at 813-864-2558 or email@example.com.
About Biovest International, Inc.
Biovest International, Inc. is an emerging leader in the field of personalized immunotherapies targeting life-threatening cancers of the blood system. Developed in collaboration with the National Cancer Institute, BiovaxID® is a patient-specific, anti-lymphoma cancer vaccine, demonstrating statistically significant Phase III clinical benefit by prolonging disease-free survival in patients suffering from indolent follicular non-Hodgkin's lymphoma. BiovaxID has been granted Orphan Drug Designation for the treatment of follicular lymphoma by both the U.S. FDA and the European EMEA. Biovest has also developed and markets a proprietary line of automated hollow fiber bioreactor systems, including the innovative AutovaxID™ which is a production platform for the scalable manufacture of difficult-to-produce biologics including personalized medicines, monoclonal antibodies, cell culture vaccines and therapeutics targeting highly infectious agents. Since 1981, Biovest has been offering its clients a wide range of instrumentation and cell culture contract manufacturing services. Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the Over-the-Counter (OTC) market with the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ).
For further information, please visit: http://www.biovest.com
Special Note: Biovest expects to soon launch its new website.
Forward-Looking Statements: Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to statements about BiovaxID®, AutovaxID™, events occurring after dates hereof, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Contact: Biovest International, Inc.
Douglas Calder, Director of Investor Relations & Public Relations, 813-864-2558
Posted: June 2010